Browse EX-10 agreements

​

Exhibit 10.4

PURCHASE AGREEMENT

**THIS PURCHASE AGREEMENT **(this “Agreement”), dated as of August 11, 2026, is made by and between ARC Group International Ltd. (the “Investor”), and Lulu’s Fashion Lounge Holdings, Inc., a Delaware corporation (the “Company”).

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to Four Million Five Hundred Thousand Dollars ($4,500,000) of the Company’s common stock, par value US$0.001 per share (the “Common Stock”); and

WHEREAS, the shares of Common Stock are listed for trading on the Principal Market under the symbol “LVLU”; and

…

CREDIT AGREEMENT

                THIS CREDIT AGREEMENT is entered into as of June 10, 2026,** by and among NOBLE ROMAN’S, INC., an Indiana corporation (“Borrower”), and LAKE FOREST BANK & TRUST COMPANY, N.A., a subsidiary of Wintrust Financial Corporation **(together with its successors and assigns, “Lender”). 

WHEREAS, Borrower has requested, and Lender has agreed to provide, subject to the terms and conditions set forth in this Agreement, certain extensions of credit;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:

**ARTICLE I **

DEFINITIONS AND ACCOUNTING TERMS

1.01.** Defined Terms**.  As used in this Agreement, the following terms shall have the meanings set forth below:

…

SECOND AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT

THIS SECOND AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT (this “Agreement”) is entered into on May 12, 2026 by and among:

1.Overland Therapeutics Inc., an exempted company incorporated under the laws of the Cayman Islands (the “Company”),

2.Allogene Therapeutics, Inc., a Delaware corporation (“Allogene”), and

3.HH BioPharma Holdings Ltd., an exempted company incorporated under the laws of the Cayman Islands (“Hillhouse”).

Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Each of Allogene and Hillhouse is referred to herein as an “Shareholder” and collectively as the “Shareholders”. Capitalized terms used herein without definition have the meanings ascribed to them in the Share Exchange Agreement or the Share Distribution Agreement, as applicable.

RECITALS

…

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

FIRST AMENDMENT

to

THE AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT

This First Amendment to the Amended and Restated Strategic Collaboration Agreement (“First Amendment to ARSCA”) is effective as of 05 August 2025 (the “First Amendment to ARSCA Effective Date”) by and between Foresight Diagnostics, Inc., having a principal place of business at 2865 Wilderness Place, Boulder, CO 80301 (“Foresight”), and Allogene Therapeutics, Inc., having a principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Company”) and amends the Strategic Collaboration Agreement the Parties entered into as of January 3, 2024. Foresight and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS:

…

TERMINATION AGREEMENT

THIS TERMINATION AGREEMENT (this “Agreement”) is entered into on May 12, 2026 (the “Effective Date”) by and among Allogene Therapeutics, Inc. (“Allogene”), Overland Therapeutics (SH) Co. Ltd. (formerly known as Allogene Overland BioPharm (PRC) Co., Limited) (“OT PRC” or “Licensee”), and Overland Therapeutics Inc. (formerly known as Allogene Overland BioPharm (CY) Limited) (“OT Cayman”) (collectively the “Parties” and each a “Party”). Capitalized terms not defined herein shall have the meanings ascribed to them in the License Agreement.

WHEREAS, the Parties intend to terminate the Exclusive License Agreement dated December 14, 2020 entered into by and between Allogene and OT Cayman and subsequently assigned by OT Cayman to Overland Therapeutics (HK) Limited (formerly known as Allogene Overland BioPharma (HK) Limited (“OT HK”), and then by OT HK to OT PRC (as it may be amended, restated and/or supplemented from time to time in accordance with its terms, the “License Agreement”).

…

May 28, 2026

Dr. Zachary Roberts

Re: Employment Letter of Agreement (“Agreement”)

Dear Zach:

Allogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you continued employment on the following terms and conditions.

1.Title; Reporting; Duties.

(a)Effective as of July 1, 2026 (“Effective Date”), you shall be appointed to the position of President and Chief Executive Officer of Allogene. For clarity, your employment with Allogene shall be continuous, and nothing in this Agreement shall be deemed to constitute a termination of your employment or a new hire or rehire by the Company. Commencing on the Effective Date, you will no longer be Allogene’s Executive Vice President, Research & Development, but you will continue serving as Allogene’s Chief Medical Officer on an interim basis, to serve at the pleasure of the Company’s Board of Directors (the “Board”).

…

ITG, INC.
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

This Non-Employee Director Compensation Policy (this “Policy”) of ITG, Inc. (the “Company”), as adopted by the Board of Directors of the Company (the “Board”), effective as of June 30, 2026 (the “Effective Date”), sets forth the compensation payable to each member of the Board who is not an employee of the Company or any of its subsidiaries (each, a “Non-Employee Director”) as consideration solely for service on the Board. For the avoidance of doubt, nothing in this Policy will prohibit the Company from compensating any Non-Employee Director for services provided to the Company outside of such Non-Employee Director’s service on the Board. This Policy shall become effective on the Effective Date and shall remain in effect until it is revised or rescinded by the Board in its sole discretion at any time and from time to time.

…

May 11, 2026

Mark King

[ ]

On behalf of the Board of Directors of Jack in the Box Inc., this serves to confirm our offer to you for the position of Executive Chairman and Interim Chief Executive Officer (“Interim CEO”) of Jack in the Box Inc. (the “Company”) effective Monday, May 11, 2026.

Base Compensation:

Your monthly gross salary, equivalent to an annual salary of $1,500,000, will be paid on a bi-weekly basis equal to $57,692.31 per pay period.

Allowance:

You will receive a taxable annual technology allowance of $1,950, paid on a bi-weekly basis equal to $75 per pay period. This allowance is intended to assist with the cost of using your personal cell phone, internet, or other device for business purposes.

Annual Incentive:

You are not eligible to participate in the annual Performance Incentive Program for Jack in the Box Inc. executive officers.

Stock Award Grant:

…

ENERSYS

AWARD AGREEMENT FOR EMPLOYEES – RESTRICTED STOCK UNITS

UNDER THE 2023 EQUITY INCENTIVE PLAN

THIS AWARD AGREEMENT FOR EMPLOYEES – RESTRICTED STOCK UNITS (this “Agreement”), dated as of _____, ____, (the “Date of Grant”) is between ENERSYS, a Delaware corporation (the “Company”), and the individual identified on the signature page hereof (the “Participant”).

BACKGROUND

A.Participant is currently an employee of the Company or one of its Subsidiaries.

B.The Company desires to (i) provide Participant with an incentive to remain in the employ of the Company or one of its Subsidiaries, and (ii) increase Participant’s interest in the success of the Company by granting restricted stock units (the “Restricted Stock Units”) to Participant to acquire shares of Common Stock (“Shares”) upon the satisfaction of the terms and conditions set forth in this Agreement.

…

ENERSYS

AWARD AGREEMENT FOR EMPLOYEES – PERFORMANCE-BASED STOCK UNITS - ADJUSTED EPS

UNDER THE 2023 EQUITY INCENTIVE PLAN

THIS AWARD AGREEMENT FOR EMPLOYEES – PERFORMANCE-BASED STOCK UNITS - ADJUSTED EPS (this “Agreement”), dated as of _____, ____(the “Date of Grant”) is between ENERSYS, a Delaware corporation (the “Company”), and the individual identified on the signature page hereof (the “Participant”).

BACKGROUND

A.Participant is currently an employee of the Company or one of its Subsidiaries.

B.The Company desires to (i) provide Participant with an incentive to remain in the employ of the Company or one of its Subsidiaries, and (ii) increase Participant’s interest in the success of the Company by granting performance-based restricted stock units (the “PSUs”) to Participant to acquire, subject to the attainment of the performance goals set forth in Annex I, the number shares of Common Stock (“Shares”) to be determined in accordance with the formula set forth in Annex Iupon the satisfaction of the terms and conditions set forth in this Agreement.

…

Reed’s, Inc.
Stock Option Grant Notice
(2026 Equity Incentive Plan)

Reed’s, Inc. (the “Company”), pursuant to its 2026 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.

…

Reed’s, Inc.

RSU Award Grant Notice

(2026 Equity Incentive Plan)

Reed’s, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2026 Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.

Participant:
Date of Grant:
Vesting Commencement Date:
Number of Restricted Stock Units:

…